A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2018

At a glance

  • Drugs Cefiderocol (Primary) ; Linezolid; Meropenem
  • Indications Gram-negative infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms APEKS-NP
  • Sponsors Shionogi
  • Most Recent Events

    • 23 May 2018 Study design presented at the 114th International Conference of the American Thoracic Society
    • 17 Mar 2018 This trial has been changed from Suspended to recruiting in Spain, according to European Clinical Trials Database record.
    • 01 Dec 2017 This trial has been Suspended in Spain, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top